Q-omics provides the consensus-scored MIR4685 profile across patient tissues and cancer cell-line models. MIR4685 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR4685 is differentially expressed in 6, with the highest sampling consensus in CHOL. Additionally, MIR4685 RNA expression shows 11,821 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, CHOL, and UVM as cancer lineages where MIR4685 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4685 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4685 survival associations across molecular data types. MIR4685 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4685 RNA expression–survival associations across cancer types. High MIR4685 expression shows unfavorable associations in KIRC, LIHC and LAML, but favorable associations in BLCA, SKCM and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR4685 RNA expression.
This table summarizes MIR4685 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4685. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4685 shows higher tumor expression in CHOL, THCA, KIRP, ESCA, HNSC and KIRC. The CHOL box plot shows higher MIR4685 RNA expression in tumor versus normal tissue (log2 FC = +1.156, t-test p = .001).
This table shows molecular features associated with MIR4685 in patient tissues and cancer cell lines. In patient samples, MIR4685 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
